Global High-Priority Regulatory Events — May 18, 2026

18-05-2026

Mahanagar Telephone Nigam Limited (MTNL) has disclosed a default in payment of principal and interest totaling ₹9,339.68 Crore to seven banks as of April 30, 2026, with the oldest default dating back to August 2024. The company's total financial indebtedness stands at ₹36,545 Crore, comprising bank loans of ₹9,340 Crore, SG Bonds of ₹24,071 Crore, and a loan from DoT for paying SG Bond interest of ₹3,134 Crore, indicating severe and prolonged financial distress.

• · Defaults date back to August 2024 with individual NPA dates: UBI 12-08-2024, BOI 04-09-2024, PNB 09-09-2024, SBI 28-09-2024, UCO 28-09-2024, PSB 08-10-2024, IOB 03-02-2025.
• · Individual bank default amounts (principal + interest in ₹ Crore): UBI 4,076.83, BOI 1,227.18, PNB 512.36, SBI 381.88, UCO 293.77, PSB 200.83, IOB 2,646.83.
• · The filing references multiple prior default intimations dating back to July 2024, indicating persistent default status.

18-05-2026

Greenpanel Industries Limited submitted copies of newspaper publications of its audited financial results for the quarter and year ended March 31, 2026, as published in Financial Express and Jan Satta on May 17, 2026. The filing is a routine compliance submission; no specific financial figures are provided in this letter.

• · The audited financial results were published in Financial Express (English, all India edition) and Jan Satta (Hindi, all India edition) on May 17, 2026.
• · The filing was made on May 18, 2026, to BSE and NSE.
• · No financial figures or performance data are extractable from this filing as it only confirms publication.

18-05-2026

TVS Motor Company's Investment Committee approved the acquisition of 51,60,903 equity shares (4.90% stake) in Jana Small Finance Bank Ltd for a cash consideration of INR 193,31,19,436.71. The target generated total income of INR 6,374.76 crore and PAT of INR 326.43 crore in FY2025-26, with consistent income growth of ~17% YoY. The acquisition is part of a broader TVS VENU plan to hold up to 9.9% on a fully diluted basis, complementing its existing financial services businesses.

• · The acquisition is not a related party transaction, but GWC Family Fund Investments Pte. Ltd. (controlled by a member of the promoter group) proposes to subscribe to 68,29,909 share warrants of Jana Small Finance Bank, subject to RBI approval.
• · The transaction is expected to close within 3 months from May 18, 2026, subject to customary conditions.
• · Jana Small Finance Bank is the fourth largest Small Finance Bank by AUM and deposit size as of March 31, 2026.
• · TVS VENU has also signed definitive agreements to acquire 100% stake in PGIM India Asset Management, indicating a broader financial services expansion.

18-05-2026

18-05-2026

The National Company Law Tribunal (NCLT) Bengaluru Bench approved the resolution plan for Indus Fila Ltd (Corporate Debtor) submitted by SPG Macrocosm Ltd through SPV-Vision Textile (Resolution Applicant) on May 10, 2019. The plan was approved by the Committee of Creditors (CoC) with 69.04% votes and includes a deposit of ₹4,00,00,000 (₹4 Crore). The approval marks a positive development for the company, allowing it to avoid liquidation, though the process involved multiple plan revisions and negotiations over several months.

• · The resolution plan was originally submitted on October 10, 2018, and underwent multiple modifications before final approval on January 7, 2019.
• · The CoC rejected an earlier version of the plan (November 1, 2018) before the 270-day CIRP deadline, but an exemption of 48 days was granted extending the period to January 31, 2019.
• · Axis Bank's objection regarding enforceability of personal guarantees was rejected by the NCLT in a separate order.
• · An application by employees of Indus Fila to be heard was also dismissed.

18-05-2026

Vikas WSP Ltd., currently under Corporate Insolvency Resolution Process (CIRP), disclosed that in NCLT Chandigarh Bench hearings on 18 May 2026, only the cooperation application (IA 764/2022) was argued, while the resolution plan approval application (IA 1538/2022) could not be taken up due to shortage of time. The next hearing is scheduled for 20 May 2026, reflecting ongoing delays in the resolution process. The company remains under CIRP with no final plan approved yet.

• · The company has been under CIRP since 02 February 2022, with Mr. Darshan Singh Anand appointed as IRP/RP by NCLT Chandigarh Bench.
• · IA (I.B.C.) No. 764/2022 pertains to a Section 19(2) application seeking cooperation, which was argued; the resolution plan approval application (IA 1538/2022) could not be taken up due to shortage of time.
• · The matter is listed for further hearing on 20 May 2026.

18-05-2026

LiveRamp reported Q4 FY26 revenue of $206M (+9% YoY) and FY26 revenue of $813M (+9% YoY), with record annual operating cash flow of $168M. However, Q4 operating cash flow declined to $59M from $63M in the prior year, and FY26 non-GAAP gross margin compressed by 1 percentage point to 73%. The company also announced a definitive agreement to be acquired by Publicis Groupe for $38.50 per share in an all-cash transaction valued at $2.5B equity, representing a 30% premium to the closing price on May 15, 2026.

• · Q4 FY26 GAAP diluted EPS was $1.12 (benefited from deferred tax valuation allowance release), non-GAAP diluted EPS $0.52.
• · FY26 GAAP diluted EPS $2.24, non-GAAP diluted EPS $2.27.
• · Subscription net retention improved to 107% in Q4; platform net retention was 108%.
• · Q4 FY26 share repurchases totaled 2.8 million shares for $76M; FY26 total 7.1 million shares for $194M.
• · Remaining share repurchase authorization of $262M as of March 31, 2026, expiring December 31, 2027.
• · Appointed Kristi Argyilan to the Board of Directors on February 11, 2026.
• · LiveRamp will not host earnings conference call due to pending acquisition.
• · Transaction expected to close by end of calendar 2026, subject to shareholder approval and customary conditions.
• · Q4 FY26 GAAP operating margin of 7% expanded 14 percentage points YoY; non-GAAP operating margin 20% expanded 7 points.
• · FY26 GAAP operating margin 10% expanded 10 points; non-GAAP 22% expanded 4 points.
• · FY26 GAAP gross margin flat at 71%; non-GAAP gross margin compressed 1 point to 73%.

18-05-2026

Chiba Bank and Chiba Kogyo Bank have agreed on a 1:1 share transfer ratio for their management consolidation via a joint share transfer, forming Chiba Financial Group effective April 1, 2027. The consolidation targets FY2028 consolidated ROE of ~11%, profit attributable to owners of parent of ¥140B or more, and OHR around 40%. While Chiba Kogyo Bank has higher net assets per share (¥2,498 vs ¥1,781) and EPS forecast (¥135.48 vs ¥127.97), it pays a much lower dividend (¥10 vs ¥52), and its stock price has historically shown volatility due to speculation and a prior large shareholder stake. The 1:1 ratio falls within all valuation ranges provided by third-party appraisers.

• · Chiba Bank acquired 19.9% of Chiba Kogyo Bank shares from Ariake Capital on March 28, 2025
• · A memorandum of understanding was announced on September 29, 2025
• · The share transfer ratio of 1:1 was agreed after repeated negotiations, and falls within all three valuation ranges from both third-party appraisers (Mitsubishi UFJ Morgan Stanley Securities and Mizuho Securities)
• · Future elimination of outward preferred dividend flows through acquisition and cancellation of Chiba Kogyo Bank preferred shares is a positive factor for Chiba FG common shareholders
• · Target Tier 1 common equity capital ratio (Basel III full implementation finalization basis, excluding valuation differences on securities) of 10.5–11.5% for FY2028
• · Chiba Kogyo Bank's stock price had been volatile due to speculative reporting and the holding period by Ariake Capital, but such influences have diminished over time

18-05-2026

18-05-2026

Perma-Fix Environmental Services announced an underwritten public offering of common stock to fund capacity upgrades at its Northwest Richland facility, continued development of its patent-pending Perma-FAS technology for PFAS destruction, and general corporate purposes. Craig-Hallum is acting as sole managing underwriter. The offering is subject to market conditions, with no assurance of completion or final terms.

• · The offering is made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-283555) declared effective on December 12, 2024.
• · The preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and available on the SEC's website or from Craig-Hallum.

18-05-2026

Faraday Future announced $25M in new convertible note financing, bringing total financing to $70M over two months (including $45M from April), sufficient to support Phase 1 of its EAI robotics strategy by end of 2026. The company raised its full-year shipment target to 1,500 units and declared a shift from liquidity-driven to capital-structure-driven financing. However, only $12.5M is immediately available to the operating account; the remainder is in controlled accounts subject to conditions, and the company continues to face significant risks including insufficient share capital and Nasdaq compliance requirements.

• · SEC investigation concluded with no penalties.
• · Founding team has fully returned to the company.
• · The $25M convertible notes are unregistered and subject to trading restrictions.
• · Of the $25M, $12.5M is directly in the operating account; the remaining $12.5M is in controlled accounts with conditions for release.
• · The full strategic plan (upgraded from Ten-Punch Combo to Five Key Transformations) will be unveiled in YT's Investor Weekly Report on Sunday.
• · Key application scenarios: education, security inspection, reception and guided tours, performance, and university research.
• · Company expects to move EAI Vehicle business away from high-cost short-term funding toward operating cash flow, industry partnerships, and long-term capital.

18-05-2026

Estrella Immunopharma reported a net loss of $2.29M for Q1 2026, an 8.9% increase from $2.10M in Q1 2025, driven largely by a 28.5% surge in G&A expenses. However, the company improved its stockholders' deficit from ($10.37M) to ($5.27M) through a $7.24M net registered direct offering and reduced total liabilities by $4.62M, primarily by paying down $4.13M in related party accrued liabilities. Cash increased 39% to $1.93M, but operating cash burn widened dramatically to $6.70M from $0.47M year-over-year, signaling heavy near-term cash consumption.

• · R&D expenses were approximately 61% of total operating expenses in Q1 2026, with $1.375M from related party (same as prior year).
• · G&A expenses increased 28.5% YoY to $891,789, partly due to stock-based compensation of $146,714 in Q1 2026 vs $159,095 in Q1 2025.
• · The company issued 4,063,290 shares of common stock, prefunded warrants, and common stock warrants in a registered direct offering, generating gross proceeds of $7,999,988 but incurring $758,882 in transaction costs.
• · Warrants outstanding surged from 2,214,993 to 10,178,928, with 8,594,935 new warrants granted at a weighted average exercise price of $1.23 (down from $11.50).
• · Aggregate intrinsic value of stock options fell from $2.682M to $0.882M, indicating a significant drop in the company's stock price.
• · Net cash used in operating activities was $6.70M, largely due to a $4.125M payment of related party accrued liabilities.
• · The company had no revenue and remains in the development stage with an accumulated deficit of $39.28M.

18-05-2026

18-05-2026

OLB Group reported a 28.6% decline in total revenue to $1.66M for Q1 2026 compared to $2.32M in Q1 2025, driven by sharp drops in transaction fees (−$540,506) and bitcoin mining revenue (−$37,262). Net loss improved slightly from $1.09M to $1.08M, but operating loss widened to $1.27M from $0.85M. However, cash surged from $15,777 to $2.33M and stockholders' equity nearly doubled to $8.10M, primarily due to $2.62M in prefunded warrant sales and $1.10M in common stock issuances.

• · Accounts payable decreased from $4.46M to $3.72M, partly due to $437K in common stock issued for settlement.
• · Net cash used in operations increased sharply from $156K to $1.34M, reflecting worsening operating cash flows.
• · The company sold 2,166,666 common shares for $1.10M and issued prefunded warrants for $2.62M.
• · Accumulated deficit widened from $74.45M to $75.53M.
• · Weighted average shares outstanding surged from 2.36M to 12.89M, diluting EPS from ($0.47) to ($0.08).

18-05-2026

iSpecimen Inc. reported a sharp 85.2% decline in revenue to $156,009 for Q1 2026 compared to $1,057,510 in Q1 2025, driven by a 86.2% drop in specimen revenue. Net loss widened 37.2% to $2,275,221 from $1,658,396, and cash used in operations nearly tripled to $3,361,846. However, the company reduced operating expenses slightly (flat at ~$2.69M) and benefited from a $261,525 gain on debt settlement, while net loss per share improved from ($28.55) to ($6.66) due to a 5.3x increase in weighted average shares outstanding.

• · Gain on debt settlement of $261,525 in Q1 2026 (none in Q1 2025).
• · Bad debt expense dropped sharply from $111,041 to $368 year-over-year.
• · Sales and marketing expense surged 344.2% to $1,542,297, while technology expense fell 54.6% to $247,549.
• · Total operating expenses remained virtually flat at $2,694,412 vs $2,695,899.
• · The company converted 3,830 shares of Series C convertible preferred stock into 497,280 common shares during Q1 2026.
• · Cash used in investing activities was $700,000 for internally developed software (none in prior year).
• · Accumulated deficit grew to $84,625,370 from $82,350,149.
• · Net loss per share improved from ($28.55) to ($6.66) due to significant share dilution (weighted average shares increased from 58,078 to 341,377).
• · Accounts receivable increased to $132,848 from $48,298, while accounts payable decreased to $4,707,393 from $5,362,604.

18-05-2026

18-05-2026

IMA Tech reported Q3 FY2026 revenues of $0, down from $27,274 in the prior year quarter, and a net loss of $14,433 compared to net income of $1,330. For the nine months, revenues increased 67% to $70,126 but net loss widened to $37,232. Cash declined to $397 from $4,500 at year-end, and stockholders' deficit increased to $(82,873). However, operating cash flow improved significantly to $(24,823) from $(77,885), and general & administrative expenses were cut to $201 in Q3 from $11,712.

• · 2,500,000 common shares were cancelled during the nine months ended January 31, 2026, reducing outstanding shares from 5,109,878 to 2,609,878.
• · Loan from related parties increased to $273,518 as of January 31, 2026 from $252,798 at April 30, 2025.
• · Accumulated deficit grew to $(120,169) from $(82,937) at year-end.
• · Amortization expense remained constant at $14,232 per quarter and $42,695 for each nine-month period.
• · No proceeds from sale of common stock in the current nine months versus $28,647 in the prior period.
• · Prepaid expenses increased to $26,135 from $4,900, a significant rise.

18-05-2026

18-05-2026

GMR Solutions Inc. entered into a Tax Receivable Agreement (TRA) on May 14, 2026, with KKR GMR Consolidated Aggregator LLC and other parties, effective upon the IPO closing date. The TRA provides for payments to TRA parties based on realized tax benefits from tax attributes and imputed interest, with payment mechanisms, subordination, and change-of-control provisions. No specific monetary amounts or financial impacts are disclosed in the filing excerpt.

• · The TRA defines 'Change of Control' events (e.g., acquisition of >50% voting power, merger, liquidation) that can trigger accelerated payment obligations.
• · The agreement includes a subordination clause (Article V) prioritizing payments under the TRA over certain other obligations.
• · Disputes under the TRA are to be resolved through an expert determination process (Section 7.9) or litigation in Delaware.
• · The TRA contains confidentiality provisions and a TRA Party Representative (KKR GMR Consolidated Aggregator LLC) to act on behalf of all TRA parties.

18-05-2026

Brand Engagement Network Inc. entered into a definitive Reseller Agreement with Accelevate Solutions on May 14, 2026, granting its subsidiary SKYE AI USA, LLC exclusive rights to the African continent for an initial five-year term, subject to annual renewal based on minimum revenue thresholds. The licensor will receive 35% of gross revenue (excluding hardware) from sales. While this expands the company's footprint in Africa, the revenue-sharing obligation and performance-based renewal introduce future financial commitments and uncertainties.

• · The agreement includes a joint Pricing Committee and standard indemnification and confidentiality provisions.
• · Exclusive rights are subject to annual renewal based on minimum revenue thresholds for subsequent consecutive years.
• · The Company previously disclosed a letter agreement with Accelevate on April 22, 2026, which led to this definitive agreement.
• · The Company is an emerging growth company and has elected not to use the extended transition period for complying with new financial accounting standards.

18-05-2026

Bitcoin Depot Inc. filed an 8-K on May 18, 2026, reporting multiple material events including a bankruptcy or receivership (Item 1.03), triggering events that accelerate direct financial obligations (Item 2.04), and departure of directors or officers (Item 5.02). The filing indicates a severe financial distress leading to bankruptcy proceedings, but specific financial details, dollar amounts, and names are not disclosed in the provided summary.

• · Filing includes multiple 8-K items (1.03, 2.04, 5.02, 7.01, 9.01) indicating a comprehensive material event.
• · Exact dollar amounts, share counts, and specific executive names are NOT_DISCLOSED in the provided summary.
• · Sector not specified; Bitcoin Depot Inc. is a Bitcoin ATM operator (known from public information, but not in filing).

18-05-2026

Flux Power Holdings, Inc. entered into a committed equity facility with Roth Principal Investments, LLC, allowing the company to sell up to $40,000,000 of common stock at its sole discretion over a 36-month period. The agreement includes multiple purchase mechanisms (Market Open, Intraday, Pre-Market, Post-Market) and conditions such as a minimum stock price threshold of $0.50 per share. This facility provides potential capital but may lead to dilution for existing shareholders.

• · The per share purchase price for all purchase types is calculated at a fixed 3.0% discount to the applicable VWAP.
• · The registration rights agreement covers up to 38,461,538 shares of common stock.
• · The facility includes a threshold price of $0.50 per share, below which no purchases can be initiated on that trading day.
• · The company may also conduct Intraday Purchases after 10:00 a.m. and before 2:00 p.m. New York City time on qualifying trading days.
• · Pre-Market Purchases are limited to a maximum of 1,000,000 shares and up to 20% of trading volume, with notices delivered between 7:00 a.m. and 8:30 a.m. New York City time.
• · The company has no obligation to sell any shares under the agreement.

18-05-2026

CMS Info Systems Limited announced a buyback of up to 49,39,126 equity shares at ₹340 per share, for an aggregate consideration of ₹167,93,02,840 (₹167.93 Cr), through the tender offer route on a proportionate basis. The Board of Directors approved the buyback on May 14, 2026, and the public announcement was published on May 18, 2026 in Financial Express (English), Jansatta (Hindi), and Navshakti (Marathi). No financial performance data is included in this filing.

• · Buyback is on a proportionate basis through the tender offer route as per Companies Act, 2013 and SEBI (Buy-Back of Securities) Regulations, 2018.
• · The buyback price of ₹340 per share represents a premium to the face value of ₹10.
• · Public announcement published in Financial Express (English, all editions), Jansatta (Hindi, all editions), and Navshakti (Marathi, Mumbai edition).
• · Board resolution approving the buyback was passed on May 14, 2026.

18-05-2026

Wyndham Hotels & Resorts CEO Geoff Ballotti disclosed his diagnosis of Multiple Myeloma, a treatable form of bone cancer, which was caught early. He stated his prognosis is favorable and that he will continue working largely as usual while reducing travel, with the full support of the Board. The company reaffirmed its strong start to the year and confidence in delivering value to stakeholders.

• · Geoff Ballotti has been with Wyndham for nearly 20 years.
• · His diagnosis followed two months of chest and back pain initially attributed to an exercise injury.
• · Treatment has begun at Beth Israel/Dana-Farber in Boston, one of the world's leading cancer centers.
• · The Board was notified last week and supports the CEO's continued engagement with reduced travel.

18-05-2026

18-05-2026

Context Therapeutics entered into an amendment to its exclusive license agreement with BioAtla for CT-202, its Nectin-4 x CD3 T cell engager. The amendment removes all future milestone and royalty obligations in exchange for a $4.5 million upfront payment and a second $2.0 million payment due by August 1, 2026, granting Context a fully paid-up, non-terminable license. The company expects to initiate a Phase 1 clinical trial for CT-202 in the third quarter of 2026.

• · CT-202 targets Nectin-4, a cell surface protein overexpressed in bladder, colorectal, lung, and breast cancers.
• · CT-202 is a pH-dependent TCE designed for preferential activity within the tumor microenvironment.
• · The clinical trial identifier for the Phase 1 study is NCT07545122.
• · Context's pipeline includes CTIM-76 (Claudin 6 x CD3 TCE) and CT-95 (Mesothelin x CD3 TCE).

18-05-2026

Ashok Leyland Limited has informed the stock exchanges that a Board meeting is scheduled on May 28, 2026 to consider and approve the standalone and consolidated audited financial results for the quarter and year ended March 31, 2026, along with a proposal for a final dividend and the issuance of Non-Convertible Debentures on a private placement basis. The trading window for designated persons has been closed from April 1, 2026 until 48 hours after the results are made public.

• · The Board will consider a final dividend for FY2026.
• · The company plans to issue Non-Convertible Debentures on a private placement basis in one or more tranches/series.
• · Trading window closure period: from April 1, 2026 until 48 hours after the financial results are made public.

18-05-2026

lululemon athletica inc. filed its definitive proxy statement for the 2026 annual meeting, highlighting the appointment of Heidi O'Neill as the next chief executive officer (effective September 8, 2026) following Calvin McDonald's departure in December 2025. The board also appointed Martha Morfitt as executive chair to support interim co-CEOs during the transition. While 83% of votes cast supported the say-on-pay proposal at the 2025 meeting, the compensation committee made no direct changes to the program in response to the vote, maintaining existing design.

• · Non-employee directors receive an annual restricted stock award with a fair value of approximately $160,000, subject to one-year vesting.
• · The board enforces limits on outside activities: current CEO directors may serve on no more than two additional public company boards; non-executive directors on no more than four.
• · The audit committee oversees cybersecurity risks via a dedicated subcommittee that meets quarterly with management.
• · The company's enterprise risk management program is led by senior leaders and coordinated by cross-functional teams; results are shared regularly with the board.
• · The next advisory vote on the frequency of say-on-pay will occur no later than the 2029 annual meeting.

18-05-2026

Gossamer Bio, Inc. filed an 8-K on May 18, 2026, reporting multiple material events including entry into a definitive agreement (Item 1.01), results of operations (Item 2.02), officer changes (Item 5.02), Regulation FD disclosure (Item 7.01), and other events (Item 8.01). However, the filing content is not provided in the query, so specific financial metrics, transaction details, and officer names are unavailable. The filing is multi-item and likely mandatory due to the inclusion of financial results. Without actual data, a directional assessment is not possible.

18-05-2026

18-05-2026

LanzaTech Global, Inc. entered into a securities purchase agreement to sell 2,000,000 shares of common stock at $10.00 per share in a registered direct offering, generating gross proceeds of $20.0 million. Concurrently, the company amended its existing subscription agreement with LanzaTech Global SPV, LLC, lowering the cash balance threshold for additional share purchases from $40 million to $30 million. Net proceeds from the offering will be used for general corporate purposes.

• · The offering was conducted under an effective shelf registration statement on Form S-3 (File No. 333-279239).
• · Closing of the offering is expected on May 18, 2026.
• · The PIPE subscription amendment also provided that LT Global consented to the offering in connection with its consent rights over future financings.
• · The Company has until May 13, 2027, to require LT Global to purchase up to an additional $20.0 million of shares, subject to the lowered cash requirement of $30 million.

18-05-2026

Armando Pimentel, Jr., CEO of Florida Power & Light (FPL) and named executive officer of NextEra Energy, resigned from his FPL CEO role effective May 18, 2026, and was appointed Vice Chairman of NextEra Energy. Scott Bores, currently President of FPL, succeeds him as CEO of FPL, effective the same date. The changes are part of a planned leadership succession process.

• · Armando Pimentel, Jr. resigned as CEO of FPL and was appointed Vice Chairman of NEE, both effective May 18, 2026.
• · Scott Bores, previously President of FPL, was appointed CEO of FPL effective May 18, 2026.
• · The filing is signed by Charles E. Sieving on behalf of both registrants (NEE and FPL).

18-05-2026

Machino Plastics Ltd submitted newspaper publications dated 18 May 2026 regarding (i) notice of transfer of equity shares for unclaimed dividends of FY 2018-19 to the IEPF Authority, and (ii) the 'Second 100 Days Campaign - SAKSHAM NIVESHAK' to encourage shareholders to update records and claim unclaimed dividends. The filings are routine regulatory compliance with no financial impact disclosed.

• · The company is transferring equity shares for which dividends remained unclaimed for FY 2018-19 to the IEPF Authority.
• · The Second 100 Days Campaign aims to help shareholders claim unclaimed dividends and complete KYC updates.
• · The filing includes a notice of an Extraordinary General Meeting (EGM) for proposed changes to the company's main objects, though details are not fully legible.
• · All required documents and forms (e.g., Form SH-13, Form SH-14) for share transfer and voting are available on the company/RTA website.

18-05-2026

Catheter Precision, Inc. reported Q1 2026 total revenues of $432K, a 202% increase from $143K in Q1 2025, driven by strong growth in Cardiac Electrophysiology product sales ($248K vs $143K) and the addition of a Private Aviation service segment ($184K). Net loss attributable to common stockholders improved to ($3,041K) from ($4,045K), and operating loss narrowed 35% to ($2,318K). However, cash used in operations increased 20% to ($2,796K), and the company ended the quarter with $441K in cash, down from $450K a year earlier. The quarter included an acquisition of a private aviation business, contributing $1.2M in cash outflow and adding $184K in service revenue.

• · The company acquired a private aviation business during Q1 2026, paying $1.2M in cash and issuing $4.8M in short-term notes and $5.8M in deferred consideration.
• · Goodwill increased from $0 to $9.7M and intangible assets from $15.2M to $22.3M due to the acquisition.
• · Private Aviation segment contributed $184K in service revenue (Luxe $42K, Hops $142K) and a segment net loss of $132K.
• · Cardiac Electrophysiology segment net loss was $1,558K, compared to total company net loss of $4,045K in Q1 2025 (prior period had no Private Aviation).
• · The company issued 392,608 shares of common stock and equity-classified contracts for $3.7M in proceeds during Q1 2026.
• · A deemed dividend of $1,360K was recorded on a warrant inducement offer.
• · Total liabilities increased to $25.9M from $9.2M, primarily due to acquisition-related debt.
• · The company had $9.2M in Level 3 fair value liabilities (royalties payable, deferred consideration, convertible notes).

18-05-2026

ABVC Biopharma reported no revenue for Q1 2026, with net loss widening to $1,689,937 from $944,190 in Q1 2025, a 79% increase. Operating expenses surged 127% to $1,572,472, driven primarily by a 1,514% jump in stock-based compensation ($787,374 vs $48,773). Cash and cash equivalents plummeted 79% to $140,324 from $681,480, and total assets declined 6.3% to $19.7 million, reflecting continued cash burn with no top-line revenue.

• · Cash burn accelerated: net cash used in operations was $894,243 in Q1 2026 vs $539,833 in Q1 2025, a 65.7% increase.
• · Total current assets fell 74.1% to $648,848 from $2,501,343, driven by declines in cash and due from related parties.
• · Short-term bank and other loans decreased 88.3% to $88,737 from $755,512, while convertible notes payable remained unchanged.
• · Accumulated deficit grew to $78,418,603 from $76,858,361, reflecting continued losses.
• · No revenue was generated in either period; the company remains pre-revenue.
• · Stock-based compensation of $787,374 represents 50% of total operating expenses in Q1 2026, up from 7% in Q1 2025.

18-05-2026

AstroNova, Inc. entered into a settlement agreement on May 15, 2026, resolving all claims related to the May 2024 acquisition of MTEX New Solution by AstroNova Portugal. Key terms include the transfer of an industrial property in Porto, Portugal (valued at €2.5 million) to AstroNova Portugal, waiver of lease amounts owed by MTEX, and release of personal guarantees by Mr. Ferreira. Pending arbitration proceedings in Portugal will be terminated upon property registration. The settlement removes legal uncertainties and provides AstroNova with a tangible asset without additional cash outlay.

• · The settlement includes a mutual release of all claims between the parties
• · Atlantiprestigio will waive its right to receive any amounts from MTEX under the lease agreement for the property
• · AstroNova and AstroNova Portugal agreed to cause Mr. Ferreira and his spouse to be released from certain personal guarantees for loans extended to MTEX
• · Pending arbitration proceedings in the Arbitration Center in Oporto, Portugal will be terminated upon definitive registration of the property
• · The settlement also addresses allocation of arbitration costs

18-05-2026

FOXO TECHNOLOGIES INC. filed an 8-K on May K on May 18, 2026, disclosing Item 1.01 (Entry into a Material Definitive Agreement) and Item 9.01 (Financial Statements and Exhibits). No specific terms, dollar amounts, or strategic details are provided in the summary, making it impossible to assess materiality or directional impact. The filing is multi item but lacks quantitative disclosure.

• · Filing date: May 18, 2026
• · Company: FOXO TECHNOLOGIES INC.
• · 8 K Items: 1.01 and 9.01
• · Size: 9 MB (indicates exhibits likely attached)
• · No dollar amounts, share counts, or percentage changes disclosed in the summary.

18-05-2026

Aditya Himmat Bhansali (Acquirer) has announced an open offer to acquire up to 7,80,026 equity shares (26% of fully diluted voting share capital) of P.H. Capital Ltd. at an offer price of ₹206.66 per share. The Independent Directors Committee has opined the price is justified per takeover regulations. The tendering period commences on May 19, 2026 and closes on June 2, 2026, following multiple schedule revisions from the originally planned February 2026 timeline.

• · No upward revision in the offer price; no competitive bid has been received.
• · SEBI provided its final observations on the Draft Letter of Offer on April 30, 2026, which were incorporated.
• · Letter of Offer dispatched to public shareholders on May 12, 2026.
• · Target Company submitted an application to BSE on February 2, 2026, seeking prior approval for change in control; SEBI and BSE granted approvals on May 8, 2026.
• · Corrigendum included correction of a date error on page 3 of LOF: 'Thursday, April 20, 2026' corrected to 'Thursday, April 30, 2026'.
• · Offer schedule was significantly revised from original February 2026 dates to May/June 2026 due to regulatory processing.

18-05-2026

Interarch Building Solutions Limited issued a clarification denying a market rumour that the company had approved a ₹10 crore buyback at ₹2,000 per share. The company stated the news item is factually incorrect and baseless, and that no such proposal has been considered or approved by the Board. Investors are advised to rely only on official exchange disclosures.

• · The rumour was circulating on the Groww platform and in Business Standard.
• · The company reaffirmed compliance with SEBI LODR Regulations and stated it will make appropriate disclosures when required.
• · No Board meeting has considered or approved any buyback proposal.

18-05-2026

Mrs. Pallavi Dinodia Gupta has resigned as Independent Director of Jagsonpal Pharmaceuticals Limited effective May 18, 2026, citing personal reasons, increasing professional commitments, and health considerations. She also ceased to be a member of the Audit Committee, CSR Committee, and Chairperson of the Stakeholders Relationship Committee. She confirmed no other material reasons for her resignation.

• · Mrs. Pallavi Dinodia Gupta holds directorships in IndiaMART InterMESH Limited (Independent Director), Voith Paper Fabrics India Limited (Independent Director), and Lumax Industries Limited (Independent Director).
• · She is also a member of various committees in these companies, including Audit, Nomination & Remuneration, CSR, and Stakeholder Relationship committees.
• · She confirmed that there are no material reasons for her resignation other than those mentioned in her letter.

18-05-2026

18-05-2026

BIL Vyapar Limited (formerly Binani Industries Limited) informed stock exchanges that the eleventh meeting of the Committee of Creditors will be held on May 19, 2026, under the Corporate Insolvency Resolution Process (CIRP). This is a procedural update with no financial figures disclosed.

• · The meeting is the eleventh meeting of the Committee of Creditors.
• · The meeting is scheduled for Tuesday, May 19, 2026.
• · Disclosure made under Regulation 30 of SEBI (LODR) Regulations, 2015, and Para 16(g) of Part A of Schedule III.
• · Company's CIN: L24117WB1962PLC025584; Corporate office in Mumbai, India.

18-05-2026

Fineotex Chemical Limited has informed the stock exchanges that the audio recording of its Q4 FY2025-2026 investor/analyst concall held on May 18, 2026, is now available on the company's website. This disclosure is made pursuant to SEBI (LODR) Regulations, 2015. No financial figures or performance details are included in this filing.

18-05-2026

IDBI Bank Ltd announced the cessation of Bombay announced the cessation of Shri Samaresh Parida and Shri Jambunathan Narayanan as Independent Directors effective May 18, 2026, due to completion of their two terms. This is a routine board composition change with no financial implications.

18-05-2026

Sunsky Logistics Limited filed a statement with BSE confirming no deviation in the utilization of IPO proceeds of ₹1683.60 Lakhs raised on October 6, 2025, for the half year ended March 31, 2026. All objects—purchase of flatbed trailers, repayment of borrowings, working capital, general corporate purposes, and public issue expenses—were fully utilized as per the original allocation, with a minor unutilized amount of ₹0.33 Lakhs in public issue related expenses noted in the auditor's certificate but not classified as a deviation.

• · IPO funds were raised on October 6, 2025, and the report covers the half year and year ended March 31, 2026.
• · The auditor's certificate shows a minor unutilized amount of ₹0.33 Lakhs in public issue related expenses, but the company's statement declares no deviation.
• · No monitoring agency was appointed as applicable.
• · All original objects remained unchanged; no shareholder approval was sought for any deviation.